Lineage Cell Therapeutics
LCTX
LCTX
115 hedge funds and large institutions have $208M invested in Lineage Cell Therapeutics in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
13% more funds holding
Funds holding: 102 → 115 (+13)
7.8% more ownership
Funds ownership: 37.32% → 45.12% (+7.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
115
Holding in Top 10
3
Calls
$818K
Puts
$514K
Top Buyers
| 1 | +$17.3M | |
| 2 | +$5.56M | |
| 3 | +$5.14M | |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$3.8M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.06M |
Top Sellers
| 1 | -$3.35M | |
| 2 | -$2.64M | |
| 3 | -$785K | |
| 4 |
HF
HRT Financial
New York
|
-$679K |
| 5 |
Goldman Sachs
New York
|
-$526K |